產品資訊 - SKYPE:daisybabychen,CAS 58-22-0 Testoviron Raw Testosterone Powder Virilon Steroids For Breast Cance->pharmaceutical raw materials

登入

加入會員

求助

HuBei Yuancheng Gongchuang Technology Co .Ltd.

	Recommended Results

SKYPE:daisybabychen,CAS 58-22-0 Testoviron Raw Testosterone Powder Virilon Steroids For Breast Cance

產品分類 :

化學->藥品->配藥原料

SKYPE:daisybabychen,CAS 58-22-0 Testoviron Raw Testosterone Powder Virilon Steroids For Breast Cance

產品規格

Model No:	58-22-0

Country	CN
Brand	yuancheng
Materials	poeder
Color	white
Packing	Pseudo-packaging
Minimum Order	10g
Payment Term	Western Union,Money Gram,T/T，Bitcoin

產品描述

SKYPE:daisybabychen,CAS 58-22-0 Testoviron Raw Testosterone Powder Virilon Steroids For Breast Cancer

1. Quick Detail (skype:daisybabychen)

Product name Testosterone Base
Other name Testoviron; Oreton; Testex; Testoderm; Testred; Virilon; Testolent
CAS register number 58-22-0
EINECS 200-370-5
Molecular formula C19H28O2
Molecular weight 288.42
Molecular structure
Assay 98%
Appearance White crystalline powder
Usage can be used as pharmaceutical material

Medical USES: used for of testosterone replacement therapy, male menopause syndrome, treatment of impotence, such as disease.
Sports purposes: increase the number of muscle.Some to increase the number of muscle exercise using dose could even reach 250 times the dose of treatment.
Other USES: biochemical research;Natural testosterone, control the male organ in your country and the develop
2. Product description (skype:daisybabychen)

Striant and Testoderm, have patent expirations of August 23, 2019 and November 10, 2019, respectively. The National Institutes of Health states that approximately 5 million American men do not produce enough of the hormone testosterone. Axiron is a highly profitable testosterone replacement therapy, with a patent expiration of February 19, 2017. The testosterone replacement Axiron generated over $48 million dollars in profit in 2011.

Coined "The Wittert Study", after Gary Wittert who is the leader of this study, this novel study is banking on being the first of many to address the worldwide epidemic of type 2 diabetes using testosterone treatment as a preventative. The International Diabetes Federation has stated that the cost to treat type 2 diabetes worldwide now hovers at 471 billion dollars.